Adherence to clinical practice guidelines for using electroconvulsive therapy in elderly depressive patients.


Journal

BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559

Informations de publication

Date de publication:
03 Jul 2024
Historique:
received: 05 01 2024
accepted: 25 06 2024
medline: 4 7 2024
pubmed: 4 7 2024
entrez: 3 7 2024
Statut: epublish

Résumé

Electroconvulsive therapy (ECT) is one of the most effective treatments in mood disorders, mainly in major depressive episode (MDE) in the context of either unipolar (MDD) or bipolar disorder (BD). However, ECT remains a neglected and underused treatment. Older people are at high risk patients for the development of adverse drug reactions. In this context, we sought to determine the duration of MDEs and the number of lines of treatment before the initiation of ECT in patients aged 65 years or over according to the presence or absence of first-line indications for using ECT from international guidelines. In this multicenter, retrospective study including patients aged 65 years or over with MDEs in MDD or BD who have been treated with ECT for MDEs, data on the duration of MDEs and the number of lines of treatment received before ECT were collected. The reasons for using ECT, specifically first-line indications (suicidality, urgency, presence of catatonic and psychotic features, previous ECT response, patient preference) were recorded. Statistical comparisons between groups used standard statistical tests. We identified 335 patients. The mean duration of MDEs before ECT was about 9 months. It was significantly shorter in BD than in MDD- about 7 and 10 months, respectively. The co-occurrence of chronic medical disease increased the duration before ECT in the MDD group. The presence of first-line indications for using ECT from guidelines did not reduce the duration of MDEs before ECT, except where there was a previous response to ECT. The first-line indications reduced the number of lines of treatment before starting ECT. Even if ECT seems to be a key treatment in the elderly population due to its efficacity and safety for MDEs, the delay before this treatment is still too long.

Identifiants

pubmed: 38961386
doi: 10.1186/s12888-024-05933-7
pii: 10.1186/s12888-024-05933-7
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

487

Informations de copyright

© 2024. The Author(s).

Références

Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004;20:13–20.
doi: 10.1097/00124509-200403000-00004 pubmed: 15087991
UK Ect Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361:799–808.
doi: 10.1016/S0140-6736(03)12705-5
Meyer JP, Swetter SK, Kellner CH. Electroconvulsive therapy in geriatric psychiatry: a selective review. Clin Geriatr Med. 2020;36:265–79.
doi: 10.1016/j.cger.2019.11.007 pubmed: 32222301
Østergaard SD, Speed MS, Kellner CH, Mueller M, McClintock SM, Husain MM, et al. Electroconvulsive therapy (ECT) for moderate-severity major depression among the elderly: data from the pride study. J Affect Disord. 2020;274:1134–41.
doi: 10.1016/j.jad.2020.05.039 pubmed: 32663942 pmcid: 7363967
van Diermen L, van den Ameele S, Kamperman AM, Sabbe BCG, Vermeulen T, Schrijvers D, et al. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. Br J Psychiatry J Ment Sci. 2018;212:71–80.
doi: 10.1192/bjp.2017.28
Eranti SV, McLoughlin DM. Electroconvulsive therapy - state of the art. Br J Psychiatry J Ment Sci. 2003;182:8–9.
doi: 10.1192/bjp.182.1.8
Leiknes KA, Jarosh-von Schweder L, Høie B. Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav. 2012;2:283–344.
doi: 10.1002/brb3.37 pubmed: 22741102 pmcid: 3381633
Sienaert P, Falconieri T, Obbels J, van den Ameele H, Bouckaert F. Improving practice in electroconvulsive therapy: a nationwide survey in Belgium. J ECT. 2016;32:29–32.
doi: 10.1097/YCT.0000000000000260 pubmed: 26252554
Chatham AN, Shafi H, Hermida AP. The use of ECT in the elderly-looking beyond depression. Curr Psychiatry Rep. 2022;24:451–61.
doi: 10.1007/s11920-022-01353-0 pubmed: 35829850
Bayes AJ, Parker GB. Comparison of guidelines for the treatment of unipolar depression: a focus on pharmacotherapy and neurostimulation. Acta Psychiatr Scand. 2018;137:459–71.
doi: 10.1111/acps.12878 pubmed: 29577229
Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49:1087–206.
doi: 10.1177/0004867415617657 pubmed: 26643054
Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section “Discussion”. Neurostimulation Treatments. Can J Psychiatry Rev Can Psychiatr. 2016;61:561–75.
doi: 10.1177/0706743716660033
Weiss A, Hussain S, Ng B, Sarma S, Tiller J, Waite S, et al. Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of electroconvulsive therapy. Aust N Z J Psychiatry. 2019;53:609–23.
doi: 10.1177/0004867419839139 pubmed: 30966782
Samalin L, Yrondi A, Charpeaud T, Genty JB, Blanc O, Sauvaget A, et al. Adherence to treatment guidelines in clinical practice for using electroconvulsive therapy in major depressive episode. J Affect Disord. 2020;264:318–23.
doi: 10.1016/j.jad.2020.01.004 pubmed: 32056767
Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet Lond Engl. 2007;370:185–91.
doi: 10.1016/S0140-6736(07)61092-7
Dominiak M, Antosik-Wójcińska AZ, Wojnar M, Mierzejewski P. Electroconvulsive therapy and age: effectiveness, safety and tolerability in the treatment of major depression among patients under and over 65 years of age. Pharm Basel Switz. 2021;14:582.
Henry C, Etain B, Mathieu F, Raust A, Vibert J-F, Scott J, et al. A French network of bipolar expert centres: a model to close the gap between evidence-based medicine and routine practice. J Affect Disord. 2011;131:358–63.
doi: 10.1016/j.jad.2010.11.013 pubmed: 21144593
Yrondi A, Bennabi D, Haffen E, Garnier M, Bellivier F, Bourgerol T, et al. Significant need for a French network of expert centers enabling a better characterization and management of treatment-resistant depression (Fondation FondaMental). Front Psychiatry. 2017;8:244.
doi: 10.3389/fpsyt.2017.00244 pubmed: 29225582 pmcid: 5706526
Dagani J, Signorini G, Nielssen O, Bani M, Pastore A, de Girolamo G, et al. Meta-analysis of the interval between the onset and management of bipolar disorder. Can J Psychiatry. 2017;62:247–58.
doi: 10.1177/0706743716656607 pubmed: 27462036
Griffiths C, O’Neill-Kerr A. Patients’, Carers’, and the Public’s perspectives on electroconvulsive therapy. Front Psychiatry. 2019;10:304.
doi: 10.3389/fpsyt.2019.00304 pubmed: 31133895 pmcid: 6514218
Gallini A, Andrieu S, Donohue JM, Oumouhou N, Lapeyre-Mestre M, Gardette V. Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2014;24:95–104.
doi: 10.1016/j.euroneuro.2013.09.003
Delva NJ, Graf P, Patry S, Gosselin C, Milev R, Gilron I, et al. Access to electroconvulsive therapy services in Canada. J ECT. 2011;27:300–9.
doi: 10.1097/YCT.0b013e318222b1b8 pubmed: 21983755
Lin Y, Tootoo J, Allen MK, Pinjari OF, Soares JC, Selek S. Geographical access to electroconvulsive therapy services in Texas. J Affect Disord. 2019;245:1135–8.
doi: 10.1016/j.jad.2018.12.013 pubmed: 30699857
Geduldig ET, Kellner CH. Electroconvulsive therapy in the elderly: new findings in geriatric depression. Curr Psychiatry Rep. 2016;18:40.
doi: 10.1007/s11920-016-0674-5 pubmed: 26909702
Beghi M, Butera E, Cerri CG, Cornaggia CM, Febbo F, Mollica A, et al. Suicidal behaviour in older age: a systematic review of risk factors associated to suicide attempts and completed suicides. Neurosci Biobehav Rev. 2021;127:193–211.
doi: 10.1016/j.neubiorev.2021.04.011 pubmed: 33878336
McCall WV, Cohen W, Reboussin B, Lawton P. Effects of mood and age on quality of life in depressed inpatients. J Affect Disord. 1999;55:107–14.
doi: 10.1016/S0165-0327(98)00204-3 pubmed: 10628879
McCall WV, Reboussin D, Prudic J, Haskett RF, Isenberg K, Olfson M, et al. Poor health-related quality of life prior to ECT in depressed patients normalizes with sustained remission after ECT. J Affect Disord. 2013;147:107–11.
doi: 10.1016/j.jad.2012.10.018 pubmed: 23158959

Auteurs

Antoine Yrondi (A)

French Society for Biological Psychiatry and Neuropsychopharmacology, Saint Germain en Laye, France. antoineyrondi@gmail.com.
Service de Psychiatrie Et de Psychologie Médicale, Centre Expert Dépression Résistante FondaMental, CHU de Toulouse, Hôpital Purpan, ToNIC Toulouse NeuroImaging Centre, Université de Toulouse, INSERM, UPS, 330 Avenue de Grande Bretagne, 31059, Toulouse, France. antoineyrondi@gmail.com.

Olivier Blanc (O)

Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France.

Loic Anguill (L)

Service de Psychiatrie Et de Psychologie Médicale, Centre Expert Dépression Résistante FondaMental, CHU de Toulouse, Hôpital Purpan, ToNIC Toulouse NeuroImaging Centre, Université de Toulouse, INSERM, UPS, 330 Avenue de Grande Bretagne, 31059, Toulouse, France.

Christophe Arbus (C)

Service de Psychiatrie Et de Psychologie Médicale, Centre Expert Dépression Résistante FondaMental, CHU de Toulouse, Hôpital Purpan, ToNIC Toulouse NeuroImaging Centre, Université de Toulouse, INSERM, UPS, 330 Avenue de Grande Bretagne, 31059, Toulouse, France.

Ludivine Boudieu (L)

Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France.

Marie-Camille Patoz (MC)

Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France.

Adeline Arnould (A)

Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France.

Thomas Charpeaud (T)

Clinique du Grand Pré, 63830, Durtol, France.

Jean-Baptiste Genty (JB)

Université Paris-Est, UMR_S955, UPEC, Créteil, France Inserm, U955, Equipe 15 Psychiatrie Génétique, Créteil, France AP-HP, Hôpital H. Mondor-A. Chenevier, Pôle de Psychiatrie, Créteil, France Fondation FondaMental, Fondation de Cooperation Scientifique, Créteil, France.

Racan Abidine (R)

Service de Psychiatrie Et de Psychologie Médicale, Centre Expert Dépression Résistante FondaMental, CHU de Toulouse, Hôpital Purpan, ToNIC Toulouse NeuroImaging Centre, Université de Toulouse, INSERM, UPS, 330 Avenue de Grande Bretagne, 31059, Toulouse, France.

Maximilien Redon (M)

Service de Psychiatrie Et de Psychologie Médicale, Centre Expert Dépression Résistante FondaMental, CHU de Toulouse, Hôpital Purpan, ToNIC Toulouse NeuroImaging Centre, Université de Toulouse, INSERM, UPS, 330 Avenue de Grande Bretagne, 31059, Toulouse, France.

Romain Rey (R)

INSERM U1028, CNRS UMR5292, University Lyon 1, Lyon Neuroscience Research Centre, Psychiatric Disorders: From Resistance to Response ΨR2 Team, Centre Hospitalier Le Vinatier, Bron, France.

Bruno Aouizerate (B)

Pôle de Psychiatrie Générale Et Universitaire, Centre de Référence Régional Des Pathologies Anxieuses Et de La Dépression, Centre Expert Dépression Résistante FondaMental, CH Charles Perrens, Bordeaux, Laboratoire Nutrition Et Neurobiologie Intégrée (UMR INRAE 1286), Université de Bordeaux, Bordeaux, France.

Djamila Bennabi (D)

Université de Franche-Comté, UMR INSERM 1322 LINC, Service de Psychiatrie de L'adulte, CIC-1431 INSERM, CHU de Besançon, F-25030, Besançon, France.

Wissam El-Hage (W)

Clinique Psychiatrique Universitaire, Centre Expert Dépression Résistante FondaMental, CHRU de Tours, Tours, France.

Bruno Etain (B)

Département de Psychiatrie Et de Médecine Addictologique, Lariboisière-Fernand Widal GHU APHP Nord Université Paris Cité Paris, Paris, France.

Jérôme Holtzmann (J)

Service de Psychiatrie de L'adulte, CS 10217, Centre Expert Dépression Résistante FondaMental, CHU de Grenoble, Hôpital Nord, Grenoble, France.

Marion Leboyer (M)

Université Paris-Est, UMR_S955, UPEC, Créteil, France Inserm, U955, Equipe 15 Psychiatrie Génétique, Créteil, France AP-HP, Hôpital H. Mondor-A. Chenevier, Pôle de Psychiatrie, Créteil, France Fondation FondaMental, Fondation de Cooperation Scientifique, Créteil, France.

Fanny Molière (F)

Department of Emergency Psychiatry and Acute Care, CHU Montpellier, INSERM U1061, Montpellier University, Montpellier, France.

Raphaelle Marie Richieri (RM)

Pôle Psychiatrie, Centre Expert Dépression Résistante FondaMental, CHU La Conception, Marseille, France.

Florian Stéphan (F)

Service Hospitalo-Universitaire de Psychiatrie Générale Et de Réhabilitation Psycho Sociale 29G01 Et 29G02, Centre Expert Depression Résistante FondaMental, EA 7479, CHRU de Brest, Hôpital de Bohars, Brest, France.

Guillaume Vaiva (G)

University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition & Centre National de Ressources Et Résilience Pour Les Psychotraumatismes (Cn2r Lille Paris), F-59000, Lille, France.

Anne Sauvaget (A)

Nantes Université, CHU Nantes, Movement, Interactions, Performance, MIP, UR 4334, 44000, Nantes, France.
French Society for Biological Psychiatry and Neuropsychopharmacology, STEP Section (Stimulation Transcrânienne en Psychiatrie), Saint-Germain-en-Laye, France.

Emmanuel Poulet (E)

Psychiatric Emergency Service, Hospices Civils de Lyon, F-69005, Lyon, France.
France Centre Hospitalier Le Vinatier, Bron; INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, PSYR2 Team, F-69000, Lyon, France.
University Lyon 1, Villeurbanne, F-69000, Villeurbanne, France.

Emmanuel Haffen (E)

Université de Franche-Comté, UMR INSERM 1322 LINC, Service de Psychiatrie de L'adulte, CIC-1431 INSERM, CHU de Besançon, F-25030, Besançon, France.

Philippe Courtet (P)

Department of Emergency Psychiatry and Acute Care, CHU Montpellier, INSERM U1061, Montpellier University, Montpellier, France.

Philippe Fossati (P)

French Society for Biological Psychiatry and Neuropsychopharmacology, Saint Germain en Laye, France.
Control-Interoception Attention Team, Paris Brain Institute (ICM), Sorbonne University, INSERM, CNRS, APHP, Hôpital de La Pitié-Salpêtrière, DMU Neuroscience, Paris, France.

Pierre-Michel Llorca (PM)

Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France.

Ludovic Samalin (L)

French Society for Biological Psychiatry and Neuropsychopharmacology, Saint Germain en Laye, France.
Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH